MedTrace Logo

Single Dose of 7.5mg Tolvaptan Phase I Clinical Trial Protocol

NCT07166783 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-09-10

No results posted yet for this study

Summary

Pharmacokinetics, pharmacological effects and safety of single dose of 7.5mg Tolvaptan tablet in healthy male subjects

Conditions

  • Health Subjects

Interventions

DRUG

Tolvaptan

single dose oral administration of 7.5mg Tolvaptan

Sponsors & Collaborators

  • Otsuka Beijing Research Institute

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-16
Primary Completion
2011-07-04
Completion
2011-07-04

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07166783 on ClinicalTrials.gov